Royalty Pharma Plc Stock Current Asset
| RPRX Stock | USD 27.71 0.17 0.62% |
Royalty Pharma Plc fundamentals help investors to digest information that contributes to Royalty Pharma's financial success or failures. It also enables traders to predict the movement of Royalty Stock. The fundamental analysis module provides a way to measure Royalty Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Royalty Pharma stock.
At this time, Royalty Pharma's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 1.6 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 14.2 B in 2024. Royalty | Current Asset |
Royalty Pharma Plc Company Current Asset Analysis
Royalty Pharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Royalty Pharma Current Asset | 10.66 M |
Most of Royalty Pharma's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Royalty Pharma Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Royalty Current Asset Historical Pattern
Today, most investors in Royalty Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Royalty Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Royalty Pharma current asset as a starting point in their analysis.
Royalty Pharma Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Royalty Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Royalty Pharma Plc has a Current Asset of 10.66 M. This is 99.5% lower than that of the Pharmaceuticals sector and 98.99% lower than that of the Health Care industry. The current asset for all United States stocks is 99.89% higher than that of the company.
Royalty Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Royalty Pharma's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Royalty Pharma could also be used in its relative valuation, which is a method of valuing Royalty Pharma by comparing valuation metrics of similar companies.Royalty Pharma is currently under evaluation in current asset category among its peers.
Royalty Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Royalty Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0345 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.50 % | ||||
| Current Valuation | 17.47 B | ||||
| Shares Outstanding | 448.13 M | ||||
| Shares Owned By Insiders | 13.05 % | ||||
| Shares Owned By Institutions | 72.73 % | ||||
| Number Of Shares Shorted | 14.68 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 1.92 X | ||||
| Price To Sales | 7.35 X | ||||
| Revenue | 2.35 B | ||||
| Gross Profit | 1.33 B | ||||
| EBITDA | 1.49 B | ||||
| Net Income | 1.13 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 6.14 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 14.42 X | ||||
| Cash Flow From Operations | 3.03 B | ||||
| Short Ratio | 4.75 X | ||||
| Earnings Per Share | 1.50 X | ||||
| Price To Earnings To Growth | 14.93 X | ||||
| Target Price | 44.83 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 16.44 B | ||||
| Total Asset | 16.38 B | ||||
| Retained Earnings | 2.52 B | ||||
| Working Capital | 1.11 B | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 16.38 B | ||||
| Last Dividend Paid | 0.82 |
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.